[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Gan To Kagaku Ryoho
; 37(11): 2165-8, 2010 Nov.
Article
en Ja
| MEDLINE
| ID: mdl-21084819
ABSTRACT
The first patient was a 59-year-old woman who was diagnosed with invasive scirrhous carcinoma. The tumor was estrogen receptor (ER)-positive, progesterone receptor (PgR)-positive, and human epidermal growth factor receptor 2 (HER2)-positive. The patient was treated with adjuvant chemotherapy and endocrine therapy after surgery. Liver metastases developed 5 years after surgery. She was treated with trastuzumab combined with vinorelbine, paclitaxel, or docetaxel. The liver metastases increased in size, 9 years after surgery, and she was treated with lapatinib and capecitabine. The efficacy of chemotherapy was judged as a partial response. The second patient was a 74-year-old woman who was diagnosed with invasive ductal carcinoma in 2005. The tumor was ER-negative, PgR-positive, and HER2-positive; she was treated with trastuzumab and paclitaxel. She developed dyspnea in January 2010. Chest radiograph showed increased lung metastases and left pleural effusion; she was treated with lapatinib and capecitabine. Lung metastases decreased and left pleural effusion disappeared after the first cycle of chemotherapy. The efficacy of chemotherapy was judged as a partial response.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Biomarcadores de Tumor
/
Carcinoma Ductal de Mama
/
Adenocarcinoma Escirroso
/
Receptor ErbB-2
Límite:
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Año:
2010
Tipo del documento:
Article